AKTX vs. COCP, ONCT, RMTI, ANEB, DRRX, EQ, CASI, LEXX, KZR, and KRON
Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Cocrystal Pharma (COCP), Oncternal Therapeutics (ONCT), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), DURECT (DRRX), Equillium (EQ), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Kezar Life Sciences (KZR), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical preparations" industry.
Cocrystal Pharma (NASDAQ:COCP) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.
Cocrystal Pharma's return on equity of 0.00% beat Akari Therapeutics' return on equity.
Cocrystal Pharma currently has a consensus target price of $10.00, suggesting a potential upside of 344.44%. Given Akari Therapeutics' higher possible upside, equities analysts plainly believe Cocrystal Pharma is more favorable than Akari Therapeutics.
6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 25.6% of Cocrystal Pharma shares are held by insiders. Comparatively, 61.8% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cocrystal Pharma has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
Akari Therapeutics received 240 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 75.86% of users gave Cocrystal Pharma an outperform vote while only 54.47% of users gave Akari Therapeutics an outperform vote.
In the previous week, Akari Therapeutics had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Cocrystal Pharma. Akari Therapeutics' average media sentiment score of 0.96 beat Cocrystal Pharma's score of 0.50 indicating that Cocrystal Pharma is being referred to more favorably in the media.
Summary
Cocrystal Pharma and Akari Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Akari Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akari Therapeutics Competitors List
Related Companies and Tools
